Search Results

1 - 10 of 287
News Release
Researchers are asking if the precision medicine approach will reduce or eliminate the role that race plays in prescribing drugs and in health care overall.
… the complex interplay of ancestry, health, disease and drug response. … In a May 26 New England Journal of Medicine … prescribing drugs and in health care overall. "We focus on drug therapies because that's where the precision medicine … imprecise prescribing practices. This means including in drug studies people from diverse social, racial and ethnic, …
News Release
A repurposed cancer drug appears to reduce the severity of lesions and pain experienced by people with Proteus syndrome
… Jeannine Mjoseth … A repurposed cancer drug appears to reduce the severity of lesions and pain … people with Proteus syndrome, a rare genomic disease. The drug, miransertib, was well tolerated, even in children, … are some initial, though unconfirmed, indications that the drug had a beneficial effect on symptoms of Proteus …
News Release
SJS/TEN is a severe drug reactions that affect the skin, and one of the most severe of adverse reactions affecting any system in the body
… Necrolysis (SJS/TEN). SJS/TEN is the severest of adverse drug reactions that affect the skin, and one of the most … organized a workshop , in collaboration with the Food and Drug Administration (FDA) and other NIH institutes, to … factors that predispose patients to severe immune mediated drug reactions like SJS/TEN, as well as studying the …
For Patients and Families
​Pharmacogenomics combines the science of how drugs work, called pharmacology, with the science of the human genome, called genomics.​
… genetic makeup, or genome, to choose the drugs and drug doses that are likely to work best for that particular … genetic makeup, or genome, to choose the drugs and drug doses that are likely to work best for that particular … drugs have been developed with the idea that each drug works pretty much the same in everybody. But genomic …
News Release
NIH researchers have identified a gene that makes yeast resistant to a lethal toxin.
Staff
Dr. Julie Segre is chief and a senior investigator in the Translational and Functional Genomics Branch at the National Human Genome Research Institute. ​
… tools to track hospital-acquired infections of multi-drug resistant organisms, including the NIH's recent … reconstructed a polymicrobial outbreak of multi-drug resistant Acinetobacter baumannii that swept through the … microbiome, bacterial pathogens, DNA sequencing, drug resistence … Dr. Julie Segre is chief and a senior …
News Release
A team from the NIH has surmounted a major obstacle to testing potential drug therapies for a rare, genetic condition called Gaucher disease.
… has surmounted a major obstacle to testing potential drug therapies for a rare, genetic condition called Gaucher … of the disease. Using this model, they have now tested a drug compound that has successfully corrected the … patients with Parkinson's disease." … Testing Potential Drug Therapies … Related Content … NIH researchers use a new …
News Release
Investigators with The Cancer Genome Atlas Research Network have identified new potential therapeutic targets for a major form of bladder cancer.
… remodeling. Overall, the researchers identified potential drug targets in 69 percent of the tumors evaluated. They … affecting different organs look very similar. As targeted drug agents go through preclinical and clinical development, … Content … TCGA bladder cancer study reveals potential drug targets, similarities to several cancers … Investigators …
Educational Resources
Pharmacogenomics is a branch of pharmacology concerned with using DNA and amino acid sequence data to inform drug development and testing.
… with using DNA and amino acid sequence data to inform drug development and testing. … Amino Acids, Deoxyribonucleic … with using DNA and amino acid sequence data to inform drug development and testing. … Educational Resources …
News Release
NIH researchers have identified a treatment that significantly decreases the risk of stroke in children with a rare genetic disease called Deficiency of Adenosine Deaminase Type 2 (DADA2).
… reason. … Benefits of the Treatment … Anti-inflammatory drug halts strokes in children with rare disease … NIH …